Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers.
Atrial fibrillation
Biomarkers
Cardiovascular magnetic resonance
Cluster analysis
Heart failure
Phenotype
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
29
06
2023
accepted:
17
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently co-exist. There is a limited understanding on whether this coexistence is associated with distinct alterations in myocardial remodelling and mechanics. We aimed to determine if patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) represent a distinct phenotype. In this secondary analysis of adults with HFpEF (NCT03050593), participants were comprehensively phenotyped with stress cardiac MRI, echocardiography and plasma fibroinflammatory biomarkers, and were followed for the composite endpoint (HF hospitalisation or death) at a median of 8.5 years. Those with AF were compared to sinus rhythm (SR) and unsupervised cluster analysis was performed to explore possible phenotypes. 136 subjects were included (SR = 75, AF = 61). The AF group was older (76 ± 8 vs. 70 ± 10 years) with less diabetes (36% vs. 61%) compared to the SR group and had higher left atrial (LA) volumes (61 ± 30 vs. 39 ± 15 mL/m Presence of AF in HFpEF is associated with cardiac structural and functional changes together with altered expression of several fibro-inflammatory biomarkers. Distinct phenotypes exist in HFpEF which may have differing clinical outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently co-exist. There is a limited understanding on whether this coexistence is associated with distinct alterations in myocardial remodelling and mechanics. We aimed to determine if patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) represent a distinct phenotype.
METHODS
METHODS
In this secondary analysis of adults with HFpEF (NCT03050593), participants were comprehensively phenotyped with stress cardiac MRI, echocardiography and plasma fibroinflammatory biomarkers, and were followed for the composite endpoint (HF hospitalisation or death) at a median of 8.5 years. Those with AF were compared to sinus rhythm (SR) and unsupervised cluster analysis was performed to explore possible phenotypes.
RESULTS
RESULTS
136 subjects were included (SR = 75, AF = 61). The AF group was older (76 ± 8 vs. 70 ± 10 years) with less diabetes (36% vs. 61%) compared to the SR group and had higher left atrial (LA) volumes (61 ± 30 vs. 39 ± 15 mL/m
CONCLUSIONS
CONCLUSIONS
Presence of AF in HFpEF is associated with cardiac structural and functional changes together with altered expression of several fibro-inflammatory biomarkers. Distinct phenotypes exist in HFpEF which may have differing clinical outcomes.
Identifiants
pubmed: 38326736
doi: 10.1186/s12872-024-03734-0
pii: 10.1186/s12872-024-03734-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Informations de copyright
© 2024. The Author(s).
Références
Samson R, Jaiswal A, Ennezat PV, Cassidy M, Jemtel THL. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5:e002477. https://doi.org/10.1161/JAHA.115.002477 .
doi: 10.1161/JAHA.115.002477
pubmed: 26811159
pmcid: 4859363
Tromp J, Ouwerkerk W, Demissei BG, et al. Novel endotypes in heart failure: effects on guideline-directed medical therapy. Eur Heart J. 2018;39:4269–76. https://doi.org/10.1093/eurheartj/ehy712 .
doi: 10.1093/eurheartj/ehy712
pubmed: 30551207
Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128:1085–93. https://doi.org/10.1161/circulationaha.113.001475 .
doi: 10.1161/circulationaha.113.001475
pubmed: 23908348
pmcid: 3910441
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–70. https://doi.org/10.1161/CIRCULATIONAHA.118.034646 .
doi: 10.1161/CIRCULATIONAHA.118.034646
pubmed: 29792299
pmcid: 6202181
Kao DP, Lewsey JD, Anand IS, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015;17:925–35. https://doi.org/10.1002/ejhf.327 .
doi: 10.1002/ejhf.327
pubmed: 26250359
Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018;39:4277–84. https://doi.org/10.1093/eurheartj/ehy626 .
doi: 10.1093/eurheartj/ehy626
pubmed: 30325423
Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC: Heart Fail. 2017;5:565–74. https://doi.org/10.1016/j.jchf.2017.05.001 .
doi: 10.1016/j.jchf.2017.05.001
pubmed: 28711451
Santema BT, Kloosterman M, Van Gelder IC, et al. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J. 2018;39:3867–75. https://doi.org/10.1093/eurheartj/ehy421 .
doi: 10.1093/eurheartj/ehy421
pubmed: 30137304
Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation. 2020;141:4–6. https://doi.org/10.1161/CIRCULATIONAHA.119.042996 .
doi: 10.1161/CIRCULATIONAHA.119.042996
pubmed: 31887078
Galli E, Bourg C, Kosmala W, Oger E, Donal E. Phenomapping heart failure with preserved ejection fraction using machine learning cluster analysis: prognostic and therapeutic implications. Heart Fail Clin. 2021;17:499–518. https://doi.org/10.1016/j.hfc.2021.02.010 .
doi: 10.1016/j.hfc.2021.02.010
pubmed: 34051979
Ripley DP, Musa TA, Dobson LE, Plein S, Greenwood JP. Cardiovascular magnetic resonance imaging: what the general cardiologist should know. Heart. 2016;102:1589–603. https://doi.org/10.1136/heartjnl-2015-307896 .
doi: 10.1136/heartjnl-2015-307896
pubmed: 27559093
Arnold JR, Kanagala P, Budgeon CA, et al. Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. 2022;15(6):1001–11. https://doi.org/10.1016/j.jcmg.2021.11.022 .
doi: 10.1016/j.jcmg.2021.11.022
pubmed: 35033490
Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. JACC Cardiovasc Imaging. 2020;13:283–96. https://doi.org/10.1016/j.jcmg.2019.02.031 .
doi: 10.1016/j.jcmg.2019.02.031
pubmed: 31202753
Schönbauer R, Duca F, Kammerlander AA, et al. Persistent atrial fibrillation in heart failure with preserved ejection fraction: prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters. Eur J Clin Investig. 2020;50:e13184. https://doi.org/10.1111/eci.13184 .
doi: 10.1111/eci.13184
Schönbauer R, Kammerlander AA, Duca F, et al. Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation. ESC Heart Fail. 2022;9:465–75. https://doi.org/10.1002/ehf2.13723 .
doi: 10.1002/ehf2.13723
pubmed: 34866363
Kanagala P, Cheng ASH, Singh A, et al. Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. 2019;12:2291–301. https://doi.org/10.1016/j.jcmg.2018.11.031 .
doi: 10.1016/j.jcmg.2018.11.031
pubmed: 30772227
Kanagala P, Arnold JR, Singh A, et al. Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction. Int J Cardiovasc Imaging. 2021;37:255–66. https://doi.org/10.1007/s10554-020-01953-y .
doi: 10.1007/s10554-020-01953-y
pubmed: 32737707
Singh A, Chan DCS, Greenwood JP, et al. Symptom onset in aortic stenosis: relation to sex differences in left ventricular remodeling. JACC Cardiovasc Imaging. 2019;12:96–105. https://doi.org/10.1016/j.jcmg.2017.09.019 .
doi: 10.1016/j.jcmg.2017.09.019
pubmed: 29248646
Napier R, McNulty SE, Eton DT, et al. Comparing measures to assess health-related quality of life in heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6:552–60. https://doi.org/10.1016/j.jchf.2018.02.006 .
doi: 10.1016/j.jchf.2018.02.006
pubmed: 29885952
pmcid: 6026057
Picard MH, Adams D, Bierig SM, et al. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr. 2011;24:1–10. https://doi.org/10.1016/j.echo.2010.11.006 .
doi: 10.1016/j.echo.2010.11.006
pubmed: 21172594
Singh A, Horsfield MA, Bekele S, et al. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging. 2015;16:763–70. https://doi.org/10.1093/ehjci/jev007 .
doi: 10.1093/ehjci/jev007
pubmed: 25680382
Gulsin GS, Henson J, Brady EM, et al. Cardiovascular determinants of aerobic exercise capacity in adults with type 2 diabetes. Diabetes Care. 2020;43:2248–56. https://doi.org/10.2337/dc20-0706 .
doi: 10.2337/dc20-0706
pubmed: 32680830
pmcid: 7440912
Flachskampf FA, Biering-Sørensen T, Solomon SD, et al. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging. 2015;8:1071–93. https://doi.org/10.1016/j.jcmg.2015.07.004 .
doi: 10.1016/j.jcmg.2015.07.004
pubmed: 26381769
Haaf P, Garg P, Messroghli DR, et al. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18:89. https://doi.org/10.1186/s12968-016-0308-4 .
doi: 10.1186/s12968-016-0308-4
pubmed: 27899132
pmcid: 5129251
Lloyd S. Least squares quantization in PCM. IEEE Trans Inf Theory. 1982;28:129–37. https://doi.org/10.1109/TIT.1982.1056489 .
doi: 10.1109/TIT.1982.1056489
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67. https://doi.org/10.18637/jss.v045.i03 .
doi: 10.18637/jss.v045.i03
Alghofaili Y. Interpretable K-Means: Clusters Feature Importances. Understand your K-Means clusters by extracting each cluster’s most important features. https://towardsdatascience.com/interpretable-k-means-clusters-feature-importances-7e516eeb8d3c (2022).
Claus P, Omar AMS, Pedrizzetti G, Sengupta PP, Nagel E. Tissue tracking Technology for Assessing Cardiac Mechanics: principles, Normal values, and clinical applications. JACC Cardiovasc Imaging. 2015;8:1444–60. https://doi.org/10.1016/j.jcmg.2015.11.001 .
doi: 10.1016/j.jcmg.2015.11.001
pubmed: 26699113
DeVore AD, McNulty S, Alenezi F, et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19:893–900. https://doi.org/10.1002/ejhf.754 .
doi: 10.1002/ejhf.754
pubmed: 28194841
Augustine D, Lewandowski AJ, Lazdam M, et al. Global and regional left ventricular myocardial deformation measures by magnetic resonance feature tracking in healthy volunteers: comparison with tagging and relevance of gender. J Cardiovasc Magn Reson. 2013;15:8. https://doi.org/10.1186/1532-429X-15-8 .
doi: 10.1186/1532-429X-15-8
pubmed: 23331550
pmcid: 3621526
Schuster A, Morton G, Hussain ST, et al. The intra-observer reproducibility of cardiovascular magnetic resonance myocardial feature tracking strain assessment is independent of field strength. Eur J Radiol. 2013;82:296–301. https://doi.org/10.1016/j.ejrad.2012.11.012 .
doi: 10.1016/j.ejrad.2012.11.012
pubmed: 23246014
Morton G, Schuster A, Jogiya R, et al. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. J Cardiovasc Magn Reson. 2012;14:43. https://doi.org/10.1186/1532-429X-14-43 .
doi: 10.1186/1532-429X-14-43
pubmed: 22721175
pmcid: 3461471
Ayton SL, Alfuhied A, Gulsin GS, et al. The Interfield strength agreement of left ventricular strain measurements at 1.5 T and 3 T using cardiac MRI feature tracking. J Magn Reson Imaging. 2022;57:1250–61. https://doi.org/10.1002/jmri.28328 .
doi: 10.1002/jmri.28328
pubmed: 35767224
Nazir SA, Shetye AM, Khan JN, et al. Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2020;36:1133–46. https://doi.org/10.1007/s10554-020-01806-8 .
doi: 10.1007/s10554-020-01806-8
pubmed: 32152811
pmcid: 7228913
Iwano H, Pu M, Upadhya B, et al. Delay of left ventricular longitudinal expansion with diastolic dysfunction: impact on load dependence of e′ and longitudinal strain rate. Physiol Rep. 2014;2:e12082. https://doi.org/10.14814/phy2.12082 .
doi: 10.14814/phy2.12082
pubmed: 25035279
pmcid: 4187544
van Grootel RWJ, Kauling RM, Menting ME, et al. Influence of age and sex on left ventricular diastolic strain analysis. Int J Cardiovasc Imaging. 2019;35:491–8. https://doi.org/10.1007/s10554-018-1480-4 .
doi: 10.1007/s10554-018-1480-4
pubmed: 30377894
Vinereanu D, Nicolaides E, Tweddel AC, Fraser AG. "Pure" diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail. 2005;7:820–8. https://doi.org/10.1016/j.ejheart.2005.02.003 .
doi: 10.1016/j.ejheart.2005.02.003
pubmed: 15921957
Diao S-L, Xu H-P, Zhang B, Ma B-X, Liu X-L. Associations of MMP-2, BAX, and Bcl-2 mRNA and protein expressions with development of atrial fibrillation. Med Sci Monit. 2016;22:1497–507. https://doi.org/10.12659/msm.895715 .
doi: 10.12659/msm.895715
pubmed: 27141955
pmcid: 4915330
de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the heart failure association (HFA) of the European Society of Cardiology. Eur J Heart Fail. 2019;21:272–85. https://doi.org/10.1002/ejhf.1406 .
doi: 10.1002/ejhf.1406
pubmed: 30714667
Krebber MM, van Dijk CGM, Vernooij RWM, et al. Matrix Metalloproteinases and tissue inhibitors of Metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction: a systematic review and Meta-analysis. Int J Mol Sci. 2020;21:6742. https://doi.org/10.3390/ijms21186742 .
doi: 10.3390/ijms21186742
pubmed: 32937927
pmcid: 7555240
DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol. 2014;77:64–72. https://doi.org/10.1016/j.yjmcc.2014.09.016 .
doi: 10.1016/j.yjmcc.2014.09.016
pubmed: 25261607
Ali MAM, Cho WJ, Hudson B, et al. Titin is a target of matrix Metalloproteinase-2. Circulation. 2010;122:2039–47. https://doi.org/10.1161/CIRCULATIONAHA.109.930222 .
doi: 10.1161/CIRCULATIONAHA.109.930222
pubmed: 21041693
pmcid: 3057897
Freestone B, Chong AY, Lim HS, Blann A, Lip GYH. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005;37:365–72. https://doi.org/10.1080/07853890510037392 .
doi: 10.1080/07853890510037392
pubmed: 16179272
Tsai Y-C, Lee C-S, Chiu Y-W, et al. Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in chronic kidney disease. Sci Rep. 2016;6:39400. https://doi.org/10.1038/srep39400 .
doi: 10.1038/srep39400
pubmed: 27991547
pmcid: 5171919
de Oliveira AAA, de Oliveira TA, de Oliveira LA, et al. Association between angiopoietin-2 and functional cardiac remodeling in hemodialysis patients with normal left ventricular ejection. J Clin Hypertens. 2022;24:502–12. https://doi.org/10.1111/jch.14465 .
doi: 10.1111/jch.14465
Chang F-C, Chiang W-C, Tsai M-H, et al. Angiopoietin-2–induced arterial stiffness in CKD. J Am Soc Nephrol. 2014;25:1198–209. https://doi.org/10.1681/asn.2013050542 .
doi: 10.1681/asn.2013050542
pubmed: 24511140
pmcid: 4033368
Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20:291–303. https://doi.org/10.1007/s10741-015-9471-1 .
doi: 10.1007/s10741-015-9471-1
pubmed: 25716909
Soeki T, Bando S, Uematsu E, et al. Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessel. 2014;29:653–8. https://doi.org/10.1007/s00380-013-0400-8 .
doi: 10.1007/s00380-013-0400-8
Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in cardiovascular disease. Front Immunol. 2019;10:823. https://doi.org/10.3389/fimmu.2019.00823 .
doi: 10.3389/fimmu.2019.00823
pubmed: 31057548
pmcid: 6481278
Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269–79. https://doi.org/10.1161/circulationaha.114.010637 .
doi: 10.1161/circulationaha.114.010637
pubmed: 25398313
Hedman ÅK, Hage C, Sharma A, et al. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart. 2020;106:342–9. https://doi.org/10.1136/heartjnl-2019-315481 .
doi: 10.1136/heartjnl-2019-315481
pubmed: 31911501
Segar MW, Patel KV, Ayers C, et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail. 2020;22:148–58. https://doi.org/10.1002/ejhf.1621 .
doi: 10.1002/ejhf.1621
pubmed: 31637815
Guo Y, Liu L, Wang J. Adiponectin and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. Biosci Rep. 2019;39:BSR20182284. https://doi.org/10.1042/bsr20182284 .
doi: 10.1042/bsr20182284
pubmed: 31088901
pmcid: 6558722
Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74:11–8. https://doi.org/10.1016/j.cardiores.2006.10.009 .
doi: 10.1016/j.cardiores.2006.10.009
pubmed: 17140553
Rodríguez-Calvo R, Girona J, Alegret JM, et al. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol. 2017;233:R173–r184. https://doi.org/10.1530/joe-17-0031 .
doi: 10.1530/joe-17-0031
pubmed: 28420707
Patten RD, Konstam MA. Ventricular remodeling and the renin angiotensin aldosterone system. Congestive Heart Failure. 2000;6:187–92. https://doi.org/10.1111/j.1527-5299.2000.80159.x .
doi: 10.1111/j.1527-5299.2000.80159.x
pubmed: 12147951
Rusinaru D, Leborgne L, Peltier M, Tribouilloy C. Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction☆. Eur J Heart Fail. 2008;10:566–72. https://doi.org/10.1016/j.ejheart.2008.04.002 .
doi: 10.1016/j.ejheart.2008.04.002
pubmed: 18456551